Lessee, Operating Lease, Liability, Undiscounted Excess Amount of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 31 Dec 2025 was $1,054,900,000, a 16% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,054,900,000 +$146,400,000 +16% 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q4 2024 $908,500,000 +$854,100,000 +1570% 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $933,400,000 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q4 2023 $54,400,000 -$8,800,000 -14% 31 Dec 2023 10-K 15 Feb 2024 2023 FY
Q4 2022 $63,200,000 -$1,800,000 -2.8% 31 Dec 2022 10-K 10 Feb 2023 2022 FY
Q4 2021 $65,000,000 -$8,374,000 -11% 31 Dec 2021 10-K 09 Feb 2022 2021 FY
Q4 2020 $73,374,000 +$53,865,000 +276% 31 Dec 2020 10-K 11 Feb 2021 2020 FY
Q4 2019 $19,509,000 31 Dec 2019 10-K 13 Feb 2020 2019 FY
Q3 2019 $16,846,000 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $17,051,000 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $17,947,000 31 Mar 2019 10-Q 01 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.